Isotopia Molecular Imaging is a global pharmaceutical company that develops, produces, and distributes diagnostic and therapeutic radioactive isotopes and advanced PET and SPECT radiotracers. Its flagship product, the radioisotope Lutetium-177 (both C.A and N.C.A), has attracted considerable attention and exhibited great promise in treating a variety of late-stage cancers, including metastatic prostate cancer and neuroendocrine tumors. Its production facilities include an advanced nuclear pharmacy that provides radionuclide labelled compounds for PET/SPECT imaging, a cyclotron facility, and an aseptic manufacturing plant that also offers contract manufacturing services (CMO).